scholarly journals Lamotrigine-induced cutaneous adverse drug reactions: A case series

2021 ◽  
Vol 0 ◽  
pp. 1-5
Author(s):  
Ruba Farsha ◽  
Ramseena Abdurahiman ◽  
Divya Padassery ◽  
Sarita Sasidharanpillai
Keyword(s):  
Bipolar Disorder ◽  
Adverse Events ◽  
Adverse Drug Reactions ◽  
Therapeutic Dose ◽  
Case Series ◽  
Drug Reactions ◽  
Recommended Guidelines ◽  
Existing Data

Lamotrigine is used in the management of seizures and bipolar disorder. Cutaneous adverse drug reactions (CADRs) including severe forms are not uncommon following lamotrigine. Existing data suggest that the risk for adverse events could be reduced by initiating the drug at a lower dose and going for a slow titration to therapeutic dose. Here, we report four cases of lamotrigine-induced CADR. Three of the four suffered from severe drug reactions and in none of them lamotrigine was administered according to recommended guidelines.

scholarly journals Improving reporting of adverse events and adverse drug reactions following injections of Chinese materia medica

2010 ◽  
Vol 3 (1) ◽  
pp. 5-10 ◽  
Author(s):  
Zhao-Xiang Bian ◽  
Hao-Yao Tian ◽  
Lin Gao ◽  
Hong-Cai Shang ◽  
Tai-Xiang Wu ◽  
...  
Keyword(s):  
Adverse Events ◽  
Adverse Drug Reactions ◽  
Drug Reactions ◽  
Chinese Materia Medica ◽  
Materia Medica

scholarly journals Parkinsonism caused by adverse drug reactions: a case series

2011 ◽  
Vol 5 (1) ◽  
Author(s):  
Solomon O Ugoya ◽  
Emmanuel I Agaba ◽  
Comfort A Daniyam
Keyword(s):  
Adverse Drug Reactions ◽  
Case Series ◽  
Drug Reactions

scholarly journals Major Aspects of Detection and Monitoring of Adverse Reactions Associated with Cephalosporin Antibiotic Treatment

2021 ◽  
Vol 9 (1) ◽  
pp. 34-42
Author(s):  
E. Yu. Demchenkova ◽  
G. I. Gorodetskaya ◽  
I. A. Mazerkina ◽  
M. V. Zhuravleva ◽  
A. S. Kazakov ◽  
...  
Keyword(s):  
Adverse Events ◽  
Adverse Drug Reactions ◽  
Patient Information ◽  
Adverse Reactions ◽  
Stevens Johnson Syndrome ◽  
Drug Reactions ◽  
Patient Information Leaflets ◽  
Information Leaflets ◽  
Spontaneous Reports ◽  
Cephalosporin Antibiotics

Widespread use of cephalosporin antibiotics in clinical practice calls for greater attention to the risk of adverse drug reactions. Information on serious or unexpected adverse events reported during post-marketing experience is submitted to national and international pharmacovigilance databases. Analysis of these reports helps to identify new adverse drug reactions.The aim of the study was to analyse the safety profile of cephalosporin antibiotics based on spontaneous reports in the international VigiBase database.Materials and methods: the analysis of the adverse reaction profile of cephalosporin antibiotics was based on MedDRA system organ classes and included spontaneous reports submitted to VigiBase from the moment of its creation until August 2020.Results: the authors identified the most clinically significant adverse reactions for different cephalosporin generations. They compared and analysed information on adverse events in VigiBase and in patient information leaflets of medicinal products authorised in the Russian Federation. It was demonstrated that some serious events described in VigiBase spontaneous reports for V-generation cephalosporins are not included in the “Side effects” section of the patient information leaflets. According to VigiBase, the use of ceftaroline was associated with the development of generalised exfoliative dermatitis, Stevens–Johnson syndrome, tubulointerstitial nephritis, while the use of ceftolozane was associated with acute kidney injury, renal insufficiency, sepsis, pneumonia, and respiratory insufficiency.Conclusion: reporting of unexpected and serious adverse drug reactions to cephalosporin antibiotics is an important task of healthcare practitioners. Availability of information on class-specific and generation-specific serious adverse reactions will help predict and prevent their development.

scholarly journals NEUROPSYCHIATRIC ADVERSE EFFECTS OF ANTIBACTERIAL AGENTS

2021 ◽  
pp. 1-8
Author(s):  
SANTA TREASA CYRIAC ◽  
DIVYA SARA IYPE
Keyword(s):  
Adverse Effects ◽  
Adverse Events ◽  
Adverse Drug Reactions ◽  
Bacterial Growth ◽  
Antibacterial Agents ◽  
Acute Psychosis ◽  
Drug Reactions ◽  
Medical Practitioners ◽  
General Management ◽  
Neuropsychiatric Adverse Effects

Anti-bacterial are agents that inhibit bacterial growth or kills bacteria and are a sub-type of antimicrobials. These are drugs used to treat infections, but they sometimes pose a threat of adverse events. Some of these adverse events are neuropsychiatric, which are generally hard to diagnose and is often paid less attention. They account for about 30% of total Adverse drug reactions (ADRs) caused by drugs in patients without mental abnormalities. The spectrum ranges from episodes of seizure to acute psychosis. The article emphasizes the frequency of such adverse events and means to raise awareness among medical practitioners regarding the same. The various neuropsychiatric adverse effects and the agents responsible have been reviewed, along with their possible mechanisms and general management. The information for writing this review was selected by searching for keywords such as Neurotoxicity, GABA, Psychosis, Naranjo scale, and Antibiomania in databases such as Google Scholar, PubMed, Elsevier, etc. After searching the articles in the above-mentioned databases, the articles were screened concerning their importance with our work and according to their title and abstract. Additional articles were discovered by checking the references in the current study's citations. Using this method, the various neuropsychiatric adverse effects of Antibacterial agents were summarized in this review.

scholarly journals Adverse Events Associated with Nifurtimox Treatment for Chagas Disease in Children and Adults

2020 ◽  
Author(s):  
A. J. Berenstein ◽  
N. Falk ◽  
G. Moscatelli ◽  
S. Moroni ◽  
N. González ◽  
...  
Keyword(s):  
Retrospective Study ◽  
Adverse Events ◽  
Chagas Disease ◽  
Adverse Drug Reactions ◽  
Drug Tolerance ◽  
Drug Reactions ◽  
Safety Concerns ◽  
Scarce Data

BACKGROUND: Nifurtimox (NF) is one of the only two drugs currently available for Chagas disease (ChD) treatment. However, there is scarce data on NF safety, and many physicians defer or refuse NF treatment because of concerns about drug tolerance. METHODS: Retrospective study of adverse drug reactions (ADRs) associated with NF treatment of ChD. Children received NF doses of 10-15 mg/kg/day for 60-90 days, and adults 8-10 mg/kg/day for 30 days. Results: 215 children (median age: 2.6yrs, range 0-17) and 105 adults (median age: 34yrs, range 18-57) were enrolled. Overall, 127/320 (39.7%) patients developed ADRs, with an incidence of 64/105 in adults, and 63/215 in children (OR = 3.7, 95%CI [2.2;6.3]). We observed 215 ADRs, 131 in adults (median: 2 events/patient (IQR25-75= 1-3) and 84 in children (median: 1 event/patient (IQR25-75= 1-1.5) (PAdjusted < 0.001). ADRs were mainly mild and moderate. Severe ADRs were infrequent (1.2% in children and 0.9% in adults). Nutritional, central nervous and digestive systems were the most frequently affected, without differences between both groups. Treatment was discontinued in 31/320 (9.7%) patients without differences between groups. However, ADR-related discontinuations occurred more frequently in adults than in children (OR = 5.5, 95%CI = [1.5;24]). CONCLUSIONS: Our study supports the safety of NF for ChD treatment. Delaying NF treatment due to safety concerns does not seem to be supported by the evidence.

Adverse Drug Reactions outside the Hospital Two Separate Adverse Events Caused by Clopidogrel Hepatic Failure Due to Propylthiouracil Newer Antipsychotic Agent Reported to Cause Priapism

2003 ◽  
Vol 38 (4) ◽  
pp. 317-319
Author(s):  
Joel Shuster
Keyword(s):  
Adverse Events ◽  
Adverse Drug Reactions ◽  
Hepatic Failure ◽  
Antipsychotic Agent ◽  
Drug Reactions

The purpose of this feature is to heighten awareness of specific adverse drug reactions (ADRs), to discuss methods of prevention, and to promote reporting of ADRs to the FDA's medWatch program (800-FDA-1088). If you have reported an interesting preventable ADR to medWatch, please consider sharing the account with our readers.

scholarly journals Bibliometric analysis of adverse drug reactions and pharmacovigilance research activities in Nepal

2020 ◽  
Vol 11 ◽  
pp. 204209862092248
Author(s):  
Sunil Shrestha ◽  
Krisha Danekhu ◽  
Bhuvan KC ◽  
Subish Palaian ◽  
Mohamed Izham Mohamed Ibrahim
Keyword(s):  
Bibliometric Analysis ◽  
Adverse Drug Reactions ◽  
Case Reports ◽  
Research Performance ◽  
Case Series ◽  
Original Research ◽  
Drug Reactions ◽  
Drug Induced ◽  
Scientific Publications ◽  
Research Activities

Background: Bibliometric analyses have been used previously to study the measures of quality and impact of research performed in several health-related areas such as adverse drug reactions (ADRs) and pharmacovigilance (PV), etc. This method can assess the research performance of publications quantitatively and statistically. There is no evidence of bibilometric studies analyzing ADRs and PV from Nepal. Therefore, the present study aimed to assess scientific output on ADRs and PV-related research activities in Nepal using a bibliometric analysis of publications from 2004 January to December 2018, that is, 15 years. Methods: A systematic search was conducted in PubMed, Web of Science, Google Scholar, Scopus and Nepal Journal Online (NepJOL) databases. ‘Adverse Drug Reactions‘ or ‘ADRs‘ or ‘ADR‘ or ‘Adverse drug reaction‘ or ‘AE‘ or ‘Adverse Event‘ or ‘Drug-Induced Reaction‘ or ‘Pharmacovigilance‘ or ‘PV‘ and ‘Nepal‘. The search covered 15 years (January 2004 to December 2018) of study on ADRs and PV in Nepal. Only articles retrieved from databases were included, whereas published/unpublished drug bulletins, pharmacy newsletters and thesis were excluded. The articles thus retrieved were recorded, and thereafter analyzed. Word count code was used for the analysis of keywords used in the retrieved articles. Results: A total of 124 articles were retrieved, with the highest rate of publications in 2006 and 2007, with 16 papers each. Among the articles, 10 (8.1%) were published in Kathmandu University Medical Journal (KUMJ). Single papers were published in 38 different journals. Brief reports (1.6%), case reports (31.2%), case series (0.8%), education forums (0.8%), letters to the editor (5.6%), original research articles (41.9%), review articles (9.7%), short communications and short reports (8.1%) on ADRs and PV were recorded. Out of 124 papers, 52 (41.9%) were original research publications. The majority (74.1%) of research was done in the category of ADR incidence, types, prevention, and management, followed by policy and suggestions for strengthening national and regional pharmacovigilance centers of Nepal (14.5%). Conclusions: During the study years, there was an increase in scientific publications on drug safety. A total of 124 published articles were found during bibliometric analysis of ADRs and PV research activities in Nepal.

scholarly journals 5PSQ-030 Adverse drug reactions due to interaction with cobicistat or ritonavir in HIV positive patients: a case series

2020 ◽  
Author(s):  
B Montero Llorente ◽  
M Vélez-Díaz-Pallarés ◽  
B Esteban Cartelle ◽  
T Gramage Caro ◽  
MÁ Rodríguez Sagrado ◽  
...  
Keyword(s):  
Adverse Drug Reactions ◽  
Case Series ◽  
Hiv Positive ◽  
Drug Reactions

Caveat medicus: Harrowing experiences of clinicians who identify and publish near-fatal oncology associated adverse drug reactions.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. 6584-6584
Author(s):  
Ashley Caitlin Godwin ◽  
Charles L. Bennett
Keyword(s):  
New England ◽  
Adverse Drug Reactions ◽  
Adverse Drug Events ◽  
Case Series ◽  
Index Patient ◽  
Drug Reactions ◽  
Inclusion Criteria ◽  
Academic Leaders ◽  
Pharmaceutical Manufacturers ◽  
Personal Experiences

6584 Background: Less than 1-10% of adverse drug reactions are reported. It is even more rare to find clinicians who choose to publish these reports in the literature. We identified clinicians who had treated a patient for an oncology-associated serious adverse drug reaction and published these findings. This is the first study that has investigated personal experiences of clinicians choosing to publish information about serious oncology-associated drug reactions they see in their patients. Methods: Clinicians treating individual patients who developed oncology-associated serious adverse drug events were asked to participate. Inclusion criteria included having index patient information, reporting case series, and being collaborative with investigators from two National Institutes of Health funded pharmacovigilance networks. Thirty-minute interviews addressed feedback from pharmaceutical manufacturers, FDA personnel, and academic leadership, and recommendations for improving pharmacovigilance. Responses were analyzed using constant comparative methods of qualitative analysis. Results: 18 clinicians met inclusion criteria and 14 interviewees are included. Toxicities included central nervous system infections, arterial/venous thromboembolism, gastrointestinal toxicity, cardiac arrhythmias, and cancer development/progression. These investigations were frequently followed by label warnings and/or convening of Food and Drug Administration (FDA) Advisory Committee reviews of safety findings. Five studies were disseminated in four high-impact factor medical journals (JAMA, Lancet, Annals of Internal Medicine, and New England Journal of Medicine). Six clinicians received feedback characterized as supportive from academic leaders, while four clinicians received feedback characterized as negative. Responses from pharmaceutical manufacturers were characterized as negative by 12 clinicians. Responses from FDA employees were characterized as negative by six clinicians. Three clinicians recommended that pharmacovigilance should include simplified clinician reporting systems. Conclusions: Our study finds that clinicians who published reports of serious oncology-associated drug reactions experienced negative feedback from pharmaceutical manufacturers. Feedback from FDA employees and academic clinicians were viewed as supportive by some and negative by others. Most clinicians recommended that future pharmacovigilance involve big data analyses.

Sign in / Sign up

Export Citation Format

Share Document